Equities Analysts Issue Forecasts for SPRY FY2025 Earnings

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) – Research analysts at Cantor Fitzgerald reduced their FY2025 earnings per share estimates for ARS Pharmaceuticals in a report released on Thursday, August 14th. Cantor Fitzgerald analyst J. Schimmer now anticipates that the company will earn ($1.92) per share for the year, down from their previous forecast of ($1.44). The consensus estimate for ARS Pharmaceuticals’ current full-year earnings is ($0.55) per share. Cantor Fitzgerald also issued estimates for ARS Pharmaceuticals’ FY2026 earnings at ($1.01) EPS.

Separately, Wall Street Zen cut ARS Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, July 26th. One equities research analyst has rated the stock with a sell rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $31.00.

ARS Pharmaceuticals Trading Up 0.4%

Shares of NASDAQ SPRY opened at $14.53 on Monday. The stock’s 50 day moving average price is $16.85 and its two-hundred day moving average price is $14.32. ARS Pharmaceuticals has a 52-week low of $10.00 and a 52-week high of $18.90. The stock has a market capitalization of $1.44 billion, a P/E ratio of -29.65 and a beta of 0.90. The company has a quick ratio of 5.98, a current ratio of 6.17 and a debt-to-equity ratio of 0.37.

ARS Pharmaceuticals (NASDAQ:SPRY) last announced its quarterly earnings data on Wednesday, August 13th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.05). ARS Pharmaceuticals had a negative net margin of 42.74% and a negative return on equity of 21.85%. The firm had revenue of $15.72 million for the quarter, compared to analyst estimates of $12.92 million.

Insider Activity

In other news, Director Brent L. Saunders sold 120,000 shares of the firm’s stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $14.25, for a total transaction of $1,710,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Alexander A. Fitzpatrick sold 102,969 shares of the firm’s stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $14.10, for a total value of $1,451,862.90. Following the sale, the insider directly owned 89,613 shares of the company’s stock, valued at approximately $1,263,543.30. This represents a 53.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,043,118 shares of company stock worth $18,024,863 in the last quarter. 33.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On ARS Pharmaceuticals

Large investors have recently modified their holdings of the stock. Bernard Wealth Management Corp. bought a new stake in shares of ARS Pharmaceuticals during the 4th quarter worth $27,000. ANTIPODES PARTNERS Ltd purchased a new stake in shares of ARS Pharmaceuticals in the first quarter valued at $37,000. GAMMA Investing LLC lifted its holdings in shares of ARS Pharmaceuticals by 4,319.7% in the first quarter. GAMMA Investing LLC now owns 3,359 shares of the company’s stock valued at $420,000 after purchasing an additional 3,283 shares in the last quarter. PNC Financial Services Group Inc. lifted its holdings in shares of ARS Pharmaceuticals by 78,100.0% in the first quarter. PNC Financial Services Group Inc. now owns 3,910 shares of the company’s stock valued at $49,000 after purchasing an additional 3,905 shares in the last quarter. Finally, Ameritas Investment Partners Inc. lifted its holdings in shares of ARS Pharmaceuticals by 16.1% in the second quarter. Ameritas Investment Partners Inc. now owns 5,598 shares of the company’s stock valued at $98,000 after purchasing an additional 777 shares in the last quarter. 68.16% of the stock is owned by institutional investors.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.